Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01494922 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of EXC 001 in Subjects Who Have Participated in Prior Studies of EXC 001
A Phase 2 study of Reduction in Severity of Skin Scarring, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 4
- Study locations
NCT01494922 is a Phase 2 study of Reduction in Severity of Skin Scarring that has completed, run by Pfizer. The registered enrollment target is 14 participants. The trial reports 4 study locations across 3 states.
The verdict
NCT01494922, a Phase 2 study of Reduction in Severity of Skin Scarring, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to provide subjects who participated in prior studies of EXC 001 the opportunity to have their hypertrophic scars surgically revised and treated with EXC 001.
Conditions Studied
Interventions
- DRUG EXC 001 (currently called PF-06473871)
Study Locations (4)
Oregon
- Jewell Plastic Surgery Center - Eugene
- Connall Consmetic Surgery - Tualatin
Florida
- Altus Research - Lake Worth
Illinois
- Northwestern University,Division of Plastic Surgery - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2011-12-08 |
| Est. Completion | 2013-09-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01494922
The ClinicalTrials.gov registry entry for NCT01494922 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Reduction in Severity of Skin Scarring appearing as the primary indexed condition, and to 1 intervention - of which EXC 001 (currently called PF-06473871) is the first listed.
NCT01494922 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Oregon, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT01494922 about?
NCT01494922 is a clinical study titled "Safety and Efficacy of EXC 001 in Subjects Who Have Participated in Prior Studies of EXC 001". The purpose of this study is to provide subjects who participated in prior studies of EXC 001 the opportunity to have their hypertrophic scars surgically revised and treated with EXC 001.
What is the current status of trial NCT01494922?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2011-12-08. Estimated completion is 2013-09-10.
What conditions does trial NCT01494922 study?
This clinical trial studies the following conditions: Reduction in Severity of Skin Scarring.
What interventions are being tested in trial NCT01494922?
The interventions under investigation include: EXC 001 (currently called PF-06473871) (DRUG).
Who is sponsoring clinical trial NCT01494922?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01494922 being conducted?
This trial has 4 study locations across Florida, Illinois, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.